|Early Times Report|
JAMMU, Dec 1: Global spiritual leader and humanitarian, Gurudev Sri Sri Ravi Shankar called for large scale studies on effectiveness of AYUSH medicines in tackling COVID-19 through immunity building after reported success in initial researches, including key study at Frankfurt Biotechnology Innovation Center.
"I want to congratulate the Indian Government and Ministry of AYUSH for giving a platform to our traditional system of Ayurvedic medicine, so that more research can be afforded for studying the benefits of these medicines in boosting immunity and holistic health," said Gurudev Sri Sri Ravi Shankar. "We often neglect the usefulness of our traditional systems of medicine. We need to scientifically explore the benefits of these systems for wider acceptance across the globe. Not too many people outside Tamil Nadu know about the Siddha medicine, but herbal formulations based on Siddha are now being researched by German researchers."
Along with Gurudev, the other key dignitaries present were, Dr Christian Garbe, Managing Director, FIZ Frankfurt Biotechnology Innovation Center, Frankfurt; Dr Raj Manchanda from the AYUSH Department, New Delhi; Prof. Dr. K. Kanakavalli, Director General, Central Council for Research in Siddha (CCRS), Chennai, Mr Arvind Varchaswi, Managing Director, Sri Sri Tattva, and Dr M.Ravi Kumar Reddy Chief Science Officer, Sri Sri Tattva.
"We are very pleased to take initiative in this extraordinary research project and thus also to be able to make our contribution in the fight against the coronavirus," said Dr Christian Garbe, Managing Director of the FIZ, "we started the 'Ayurgenomics' research project in Mid-2020 to examine anti-inflammatory and immune-boosting Ayurvedic agents for their effectiveness against the coronavirus SARS-CoV-2."
Representing AYUSH Department, Delhi Dr Raj Manchanda said "I am happy to receive the Kabasura Kudineer tablets medicines for 10,000 people from Sri Sri Tattva for free distribution, we will be documenting the outcomes and sharing in due course."
Multiple studies are now being conducted on the immuno-modulatory effects of traditional Indian medicines, nationally and internationally.
Among them, a pivotal research study by Frankfurt Innovation Center for Biotechnology (FIZ) shows the efficacy of Kabasur Kudineer Tablet, a classical Siddha formulation, along with other Ayurveda medicines for screening inhibitors of the SARS-CoV-2 Spike: ACE2 interaction.
"We distributed Kabasura Kudineer as a prophylactic care in the state of Tamil Nadu for improving the immunity and found it effective," said Dr.Kanakavalli, DG CCRS, Chennai.